A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
With
Biogen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Body weight between 100kg and 150kg
Diagnosis of Chronic Plaque Psoriasis with Body Surface Area (BSA) involvement of ≥ 10%
Candidate for phototherapy or systemic therapy for Psoriasis
CD4 + T lymphocyte counts \> lower limit of normal
You may not be if
Clinically significant abnormal hematology values or blood chemistry values
ALT or AST value of ≥ 3x the upper limit of normal
Other types of Psoriasis
Serious infection within 3 months prior to 1st dose of study drug
Antibody positive for HIV
History of malignancy
History of severe allergic or anaphylactic reactions
History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease
Clareo Health | A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
